Joel Greenblatt’s Telomir Pharmaceuticals TELO Stock Holding History

Joel Greenblatt’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-6,770	Closed	-$229K	–	1676
2024 Q4	$229K	Buy	+6,770	New	+$31.9K	﹤0.01%	1333

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Joel Greenblatt's TELO Position: Q1 2025 in Review

Joel Greenblatt sold out of Telomir Pharmaceuticals (TELO) in Q1 2025, closing a stake of 6,770 shares — an estimated $229K sold.

Joel Greenblatt first reported a position in TELO in Q4 2024 and held it in 1 quarter. The position peaked at $229K in Q4 2024. 42 funds tracked by Wall St. Rank hold TELO as of Q1 2025.

Joel Greenblatt reported no remaining Telomir Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Joel Greenblatt sold 6,770 Telomir Pharmaceuticals shares in Q1 2025, an estimated $229K.
Joel Greenblatt first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Joel Greenblatt's Telomir Pharmaceuticals position peaked at $229K in Q4 2024.
42 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2025.

Based on Gotham Asset Management's 13F filing for Q1 2025, filed 15 May 2025.